Pancreas Cancer
Conditions
Keywords
pancreatic cancer, adenosquamous carcinoma of the pancreas, ASCP, phase II
Brief summary
The purpose of this research is to determine the benefit of pemigatinib in patients with advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.
Interventions
DRUGPemigatinib 4.5 MG
Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food.
Sponsors
Incyte Corporation
HonorHealth Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years of age; male or female * Capable of providing informed consent and complying with trial procedures. * Histologically or cytologically confirmed adenosquamous carcinoma of the pancreas (ASCP) * Metastatic or unresectable ASCP patients who have progressed on at least one line of therapy * FGFR gene fusion, mutation, or rearrangement as determined by standard CLIA-certified FDA-approved genomic panel (e.g. Ashion, Caris, FoundationOne etc.). * Radiographically measurable or evaluable disease according to RECIST 1.1 criteria. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Life expectancy ≥ 12 weeks. * Females of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy \[the surgical removal of the uterus\] or bilateral oophorectomy \[the surgical removal of both ovaries\] or (2) has not been naturally postmenopausal for at least 24 consecutive months \[i.e., has had menses at any time during the preceding 24 consecutive months\]) must: 1. Either commit to true abstinence\* from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting study treatment (including dose interruptions), and while on study treatment and for 1 week following discontinuation from study treatment ;and, 2. Have a negative serum pregnancy test (β -hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and at the end of study participation. This applies even if the subject practices true abstinence\* from heterosexual contact. * Male subjects must practice true abstinence\* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 1 week following discontinuation from study treatment, even if he has undergone a successful vasectomy.
Exclusion criteria
* Patients that have received prior treatment with a selective FGFR inhibitor * History of and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications. * Current evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination. * Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed. * Exposure to any therapeutic or investigational agent(s) within 3 weeks prior to initiation of study treatment. * Major surgery within 4 weeks prior to initiation of study treatment. * Any condition in the opinion of the principal investigator that might interfere with the patient's participation in the study or in the evaluation of the study results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate of pemigatinib | Initiation of study treatment up to 12 cycles (each cycle is 21 days) | Overall response rate of pemigatinib in patients with advanced metastatic or surgically unresectable ASCP who have progressed on previous therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | Initiation of study treatment up to study completion, up to 2 years | To determine progression free survival (PFS) |
| Overall survival (OS) | Initiation of study treatment up to study completion, up to 2 years | To determine overall survival (OS) |
| Number of participants with treatment-related adverse events as assessed by CTCAE V4.0 | Initiation of study treatment up to 12 cycles (each cycle is 21 days) | To determine the overall safety (medical risk to the subject) and tolerability (the degree to which adverse effects can be tolerated by the subject) of pemigatinib in patients with advanced metastatic or surgically unresectable ASCP who have progressed on previous therapy |
Countries
United States
Outcome results
None listed